Related Experiment Video
Updated: May 21, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine
Soo Huey Yap1, Brian D Herman, Jessica Radzio
1Retroviral Biology and Antivirals Laboratory, Centre for Virology, Burnet Institute, Melbourne, Victoria, Australia.
Abstract:
The efficacy of regimens that include both zidovudine and nevirapine can be explained by the synergistic interactions between these drugs. N348I in HIV-1 reverse transcriptase confers decreased susceptibility to zidovudine and nevirapine. Here, we demonstrate that N348I reverses the synergistic inhibition of HIV-1 by zidovudine and nevirapine. Also, the efficiency of zidovudine-monophosphate excision in the presence of nevirapine is greater for N348I HIV-1 reverse transcriptase compared with the wild-type enzyme. These data help explain the frequent selection of N348I in regimens that contain zidovudine and nevirapine, and suggest that the selection of N348I should be monitored in resource-limited settings where these drugs are routinely used.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
08:33Nucleocapsid Annealing-Mediated Electrophoresis (NAME) Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
Published on: January 19, 2015
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Retroviruses
Viruses with RNA Genomes
Subviral Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions